Citigroup Downgrades Summit Therapeutics to Neutral, Raises Price Target to $23

Benzinga · 09/27 14:01
Citigroup analyst Yigal Nochomovitz downgrades Summit Therapeutics (NASDAQ:SMMT) from Buy to Neutral and raises the price target from $19 to $23.